Monthly Archives: September 2015

Biothera’s Cancer Immunotherapy Drug Imprime PGG Elicits Increased Natural Killer Cell Activation and Cancer Cell Killing

Study Further Demonstrates Imprime’s Effect in Enlisting the Innate Immune System to Eradicate Cancer NEW YORK – Sept. 18, 2015 – Imprime PGG, Biothera’s late-stage investigational cancer immunotherapy drug, enhances the tumor killing function of the innate immune system’s Natural Killer (NK) cells, according to research presented today at Inaugural International Cancer Immunotherapy Conference jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the...

Read More


Biothera’s Imprime PGG Cancer Immunotherapy Drug Activates Dendritic Cells, Leading to Enhanced T Cell Expansion and Cytokine Production

Imprime PGG, as a PAMP, effectively activates antigen presentation and drives T cell engagement NEW YORK – Sept. 18, 2015 – New data reported today at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research, demonstrate that Biothera’s investigational cancer immunotherapy drug Imprime PGG enhances...

Read More


Imprime PGG Specifically Enhances the Potent Tumor Killing Activity of Neutrophils

Imprime PGG treatment enables neutrophils to kill cancer cells decorated with therapeutic monoclonal antibody NEW YORK – Sept. 16, 2015 – Research presented today by Biothera shows for the first time that cancer cells coated with therapeutic monoclonal antibodies are specifically recognized and killed by Imprime PGG-treated neutrophils. The findings were reported at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the...

Read More


Biothera’s Imprime PGG Enhances Anti-Tumor Activity of the Innate Immune System’s Macrophages

Research examines Imprime PGG’s effect on macrophages in engulfing human cancer cells NEW YORK – Sept. 16, 2015 – Research presented today at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research, demonstrates that Biothera’s cancer immunotherapy drug, Imprime PGG, enhances the anti-tumor activity of...

Read More


Biothera Reports Additional Biomarker Data for Predicting Response to Its Investigational Cancer Immunotherapy Drug

A genetic variant may reveal patients with the greatest likelihood for response to Imprime PGG- based therapy NEW YORK – Sept. 16, 2015 – Biothera today will present research at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research, advancing the patient selection biomarker strategy...

Read More


Biothera to Present New Data at International Cancer Immunotherapy Conference

EAGAN, MN — September 1, 2015 — Biothera will present new data to cancer researchers from around the world that expands scientific understanding of how the company’s investigational cancer immunotherapy Imprime PGG® engages both the innate and adaptive immune systems to kill antibody-targeted cancer cells. Biothera has had five research abstracts accepted for presentation at the International Cancer Immunotherapy Conference September 16-19 in New York...

Read More